Drug shortage: Methylprednisolone Acetate Injection (METHYLPREDNISOLONE ACETATE, DEPO-MEDROL)
FDA lists 23 presentations as Current. Availability: Unavailable (4), Limited Availability (9), Available (10). Reason: Shortage of an active ingredient; Demand increase for the drug. Companies: Sagent Pharmaceuticals, Pfizer Inc., Eugia US LLC, Amneal Pharmaceuticals, Par Health, USA LLC.
- Published by source
- 2021-12-15
- First seen by Reality Radar
- 2026-10-22
- Last verified
- 2026-10-22
Affected
- Manufacturer
- Sagent Pharmaceuticals
- Products
- Methylprednisolone Acetate Injection METHYLPREDNISOLONE ACETATE DEPO-MEDROL
Whether your exact unit is affected depends on the model, serial number and region in the official notice.
What the official notice says
Risk: Current — Unavailable
Remedy / actions:
- Estimated recovery: November 2026, Product on hand is 8-12 months of dating prior to expiry
- Limited Supply Available. Next Delivery: November 2026; Estimated Recovery: December 2026
Is this affecting you?
Add what you own or use and Reality Radar will tell you when official changes match it — with evidence and next steps.
Sources
- openFDA Drug Shortages Tier A · official published 2021-12-15
Evidence ledger
Every piece of evidence we store is appended to a public hash chain, so later edits are detectable. Anyone can re-verify it.
| Entry | Kind | Observed | Evidence hash | Entry hash |
|---|---|---|---|---|
| #890 | new | 2026-10-22 | 68fa998dc914…e6a24c | e4b87e58f80b…8fe735 |
Chain head: #1076 8ad5adc30b9b…88ce20